ArriVent BioPharma, Inc.

Listed Company

AVBPCIK 0001868279NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-166.31M

Total Assets

$333.17M

Equity

$307.22M

Shares Out

44.20M

Op. Cash Flow

$-160.59M

Business

ArriVent BioPharma, Inc. is a clinical‑stage biopharmaceutical company that identifies, develops and commercializes differentiated oncology medicines, with an initial focus on treatments for cancers. It develops the EGFR mutant‑selective tyrosine kinase inhibitor firmonertinib and next‑generation antibody‑drug conjugates (ADCs), advancing candidates through preclinical, IND‑enabling and clinical trials. Its key activities include internal clinical development programs, in‑licensing and commercialization arrangements, and collaborative discovery and development partnerships for ADCs. ArriVent pursues global development and commercialization outside greater China and relies on partners and third‑party contract manufacturers to support trials and supply.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research and development	153	79	65
General and administrative	24	15	10
Total operating expenses	178	94	75
Operating loss	−178	−94	−75
Interest and investment income	11	14	5
Net loss	−166	−80	−69
Unrealized gain (loss) on marketable securities	225,000	−211,000	—
Total other comprehensive gain (loss)	225,000	−211,000	—
Total comprehensive loss	−166	−81	−69
Net loss per share attributable to common stockholders, basic (in dollars per share)	−4.32	−2.56	−32.38
Net loss per share attributable to common stockholders, diluted (in dollars per share)	−4.32	−2.56	−32.38
Weighted-average shares of common stock outstanding, basic (in shares)	38	31	2
Weighted-average shares of common stock outstanding, diluted (in shares)	38	31	2

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	46	74	150	—
Short-term investments	267	145	—	—
Prepaid expenses and other current assets	20	8	10	—
Total current assets	333	227	160	—
Long-term investments	—	48	—	—
Right of use assets - operating leases	13,000	154,000	291,000	—
Deferred offering costs	69,000	—	3	—
Other assets	190,000	126,000	107,000	—
Total assets	333	275	163	—
Accounts payable	6	4	5	—
Accrued expenses	20	13	7	—
Operating lease liabilities	14,000	162,000	140,000	—
Total current liabilities	26	17	12	—
Operating lease liabilities, net of current amount	—	14,000	177,000	—
Total liabilities	26	17	12	—
Commitments and contingencies (Note 7)	—	—	—	—
Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—	—	—
Common stock $0.0001 par value, 200,000,000 shares authorized; 42,452,251 and 33,706,765 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	4,000	3,000	—	—
Additional paid-in capital	712	496	5	—
Accumulated deficit	−405	−238	−158	—
Accumulated other comprehensive income (loss)	14,000	−211,000	—	—
Total stockholders' equity	307	258	−153	−85
Total liabilities and stockholders' equity	333	275	163	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Net loss	−166	−80	−69
Stock-based compensation expense	13	3	895,000
Amortization/Accretion of bond discounts/premiums	−3	—	—
Prepaid expenses and other current assets	−13	1	10
Other assets	—	−20,000	−35,000
Accounts payable	2	−751,000	1
Accrued expenses	7	6	2
Operating lease liabilities	−21,000	−2,000	25,000
Net cash used in operating activities	−161	−70	−56
Purchase of short-term and long-term investments	−273	−194	—
Sales and maturities of short-term and long-term investments	202	2	—
Net cash used in investing activities	−71	−192	—
Proceeds from issuance of common stock, net of issuance costs	203	186	—
Proceeds from the exercise of stock options	502,000	631,000	354,000
Payment of deferred financing costs	−70,000	—	−2
Net cash provided by financing activities	203	187	43
Net decrease in cash and cash equivalents	−29	−76	−13
Deferred offering costs transferred to additional paid-in-capital	300,000	3	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro